MX380546B - Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. - Google Patents

Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.

Info

Publication number
MX380546B
MX380546B MX2016005142A MX2016005142A MX380546B MX 380546 B MX380546 B MX 380546B MX 2016005142 A MX2016005142 A MX 2016005142A MX 2016005142 A MX2016005142 A MX 2016005142A MX 380546 B MX380546 B MX 380546B
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidone
pharmaceutical applications
preparation
pyrrolotriazone
derivatives
Prior art date
Application number
MX2016005142A
Other languages
English (en)
Other versions
MX2016005142A (es
Inventor
Bin Gui
Hejun Lu
Piaoyang Sun
Qing Dong
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MX2016005142A publication Critical patent/MX2016005142A/es
Publication of MX380546B publication Critical patent/MX380546B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona derivados de pirazolopirimidona o pirrolotriazona, el método de preparación de los mismos, y las aplicaciones farmacéuticas de los mismos. Específicamente, la presente invención proporciona derivados de pirazolopirimidona o pirrolotriazona representados por una formula general (I) y las sales farmacéuticas de los mismos, el método de preparación de los mismos, y su uso como un antagonista de hormona liberadora de gonadotropina (GnRH) y, especialmente, como agentes terapéuticos para la endometriosis, en donde el definiciones de los sustituyentes en la formula general (I) son los mismos que las definiciones de la especificación.
MX2016005142A 2013-10-30 2014-09-30 Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. MX380546B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310525956 2013-10-30
PCT/CN2014/087906 WO2015062391A1 (zh) 2013-10-30 2014-09-30 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2016005142A MX2016005142A (es) 2016-10-28
MX380546B true MX380546B (es) 2025-03-12

Family

ID=53003302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005142A MX380546B (es) 2013-10-30 2014-09-30 Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.

Country Status (22)

Country Link
US (3) US10005781B2 (es)
EP (1) EP3064498B1 (es)
JP (1) JP6412563B2 (es)
CN (1) CN104884457B (es)
AU (1) AU2014344504C1 (es)
BR (1) BR112016008799B1 (es)
CA (1) CA2927641C (es)
CY (1) CY1122196T1 (es)
DK (1) DK3064498T3 (es)
ES (1) ES2747839T3 (es)
HR (1) HRP20191679T1 (es)
HU (1) HUE046314T2 (es)
LT (1) LT3064498T (es)
MX (1) MX380546B (es)
PL (1) PL3064498T3 (es)
PT (1) PT3064498T (es)
RS (1) RS59457B1 (es)
RU (1) RU2674977C2 (es)
SI (1) SI3064498T1 (es)
SM (1) SMT201900573T1 (es)
TW (1) TWI675838B (es)
WO (1) WO2015062391A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2674977C2 (ru) * 2013-10-30 2018-12-14 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
WO2018082687A1 (zh) * 2016-11-07 2018-05-11 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的多晶型及其制备方法
WO2018086608A1 (zh) 2016-11-14 2018-05-17 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
AU2018305633B2 (en) * 2017-07-28 2022-11-24 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative
CN109970662B (zh) * 2017-12-27 2023-06-30 上海科胜药物研发有限公司 一种制备噁拉戈利中间体的方法
CN117203209B (zh) * 2021-04-02 2026-05-12 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶形式及其制备方法
CN115260211B (zh) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 含噻吩稠环类衍生物、药物组合物及其制备方法和应用
WO2023030293A1 (zh) * 2021-08-30 2023-03-09 江苏恒瑞医药股份有限公司 一种GnRH受体拮抗剂的结晶工艺
CN115141809B (zh) * 2022-08-30 2023-05-02 南京诺唯赞生物科技股份有限公司 一种检测gnrh结合蛋白生物学活性的方法及试剂盒
EP4671246A1 (en) * 2023-02-24 2025-12-31 Japan Tobacco Inc. COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE
TW202448887A (zh) * 2023-02-24 2024-12-16 日商日本煙草產業股份有限公司 取代吡唑并嘧啶化合物及其醫藥用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US20020065309A1 (en) 1999-08-04 2002-05-30 Ge Peng Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists
EP1479684A4 (en) * 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
JP5072166B2 (ja) * 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
JP4039574B2 (ja) * 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
JPWO2006083005A1 (ja) * 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
JP2008533025A (ja) 2005-03-07 2008-08-21 ワイス キノキサリンジヒドロハライド二水和物およびそのための合成方法
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
ES2456515T3 (es) * 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
WO2011090935A1 (en) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN102807568B (zh) * 2011-05-31 2015-11-25 正大天晴药业集团股份有限公司 噻二唑衍生物类dpp-iv抑制剂
WO2012175514A1 (en) 2011-06-21 2012-12-27 Bayer Intellectual Property Gmbh Pyridinone derivatives and pharmaceutical compositions thereof
MX370976B (es) * 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
US9481684B2 (en) * 2012-02-28 2016-11-01 Sk Chemicals Co., Ltd. Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same
CN102807569B (zh) * 2012-08-21 2015-02-25 四川大学 一种镇静催眠的化合物及其制备方法和用途
RU2674977C2 (ru) * 2013-10-30 2018-12-14 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения

Also Published As

Publication number Publication date
EP3064498A4 (en) 2017-03-22
ES2747839T3 (es) 2020-03-11
US10005781B2 (en) 2018-06-26
DK3064498T3 (da) 2019-10-07
AU2014344504C1 (en) 2018-11-01
RU2016119135A (ru) 2017-12-04
JP2016534989A (ja) 2016-11-10
US20190270748A1 (en) 2019-09-05
PT3064498T (pt) 2019-10-14
RU2674977C2 (ru) 2018-12-14
US20180244679A1 (en) 2018-08-30
JP6412563B2 (ja) 2018-10-24
SMT201900573T1 (it) 2019-11-13
CY1122196T1 (el) 2020-11-25
US10633388B2 (en) 2020-04-28
TWI675838B (zh) 2019-11-01
CA2927641C (en) 2023-03-14
CA2927641A1 (en) 2015-05-07
RU2016119135A3 (es) 2018-05-18
RS59457B1 (sr) 2019-11-29
PL3064498T3 (pl) 2020-03-31
WO2015062391A1 (zh) 2015-05-07
AU2014344504A1 (en) 2016-05-12
BR112016008799A8 (pt) 2020-03-24
US10344034B2 (en) 2019-07-09
EP3064498B1 (en) 2019-07-17
TW201536787A (zh) 2015-10-01
CN104884457B (zh) 2016-12-07
LT3064498T (lt) 2019-10-10
US20160264578A1 (en) 2016-09-15
BR112016008799B1 (pt) 2023-02-23
AU2014344504B2 (en) 2018-07-19
HRP20191679T1 (hr) 2019-12-13
SI3064498T1 (sl) 2019-11-29
EP3064498A1 (en) 2016-09-07
MX2016005142A (es) 2016-10-28
HUE046314T2 (hu) 2020-02-28
CN104884457A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1122196T1 (el) Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
DOP2018000088A (es) Amidas heterocíclicas como inhibidores de cinasas
CY1122920T1 (el) ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CR20160099A (es) Formulación de inhibidores de la syk
MX377816B (es) Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
EA201690888A1 (ru) Новые гетероциклические соединения
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
EA201500931A1 (ru) Производные пиридин-4-ила
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2016015856A (es) Derivados de naftiridinadiona.